納芯微(688052.SH):國潤瑞祺、慧悦成長、蘇州華業及其一致行動人減持計劃實施完畢
格隆匯5月19日丨納芯微(688052.SH)公佈,近日,公司收到國潤瑞祺、慧悦成長、蘇州華業及其一致行動人長沙華業出具的《關於減持結果的吿知函》,截至2025年5月17日,上述股東減持計劃實施情況如下:
1、股東國潤瑞祺通過集中競價交易方式減持公司股份合計712,462股;通過大宗交易方式減持公司股份合計712,000股;2、股東慧悦成長通過集中競價交易方式減持公司股份合計1,425,284股;3、股東蘇州華業及其一致行動人長沙華業通過集中競價交易方式減持公司股份合計291,288股。上述股東本次減持股份計劃時間區間均已屆滿,本次減持計劃實施完畢。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.